Theravance Biopharma (TBPH) Stock: Buy, Sell, or Hold?
$17.03
+0.00 (+0.00%)
â˛
5d:
+0.0%
30d:
+0.12%
90d:
-1.39%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (64%)
Quality Score
51/100
Position
FAIR
Forward P/E & Valuation
13.4x
FAIR
vs 13.2x historical avg
Wall Street Target
$17.67
+3.7% upside
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$17.00 / $17.08
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: TBPH is fairly priced but lacks strong directional signals. At 0.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Get Alerted When TBPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$32.77
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$20.35
16.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TBPH is currently trading at $17.03, which is considered fair based on recent price action. The stock's valuation (Forward PE: 13.4) is in line with its historical norms (13.2). At these levels, the market is pricing in 0.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TBPH is in a uptrend. The price is currently testing key support at $17.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TBPH is in a uptrend. The price is currently testing key support at $17.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
51/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
63.8%
Trading Range & Key Levels
Support Level
$17.00
Resistance Level
$17.08
Current Trend
Uptrend
Technical data as of
Sep 23, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (50/100)
- NEUTRAL: Near Wall St target ($17.67)
- NEUTRAL: Market pricing in 0.5% annual earnings growth - fairly valued
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
13.36
Wall Street Target
$17.67
(+3.7%)
Revenue Growth (YoY)
-20.9%
Profit Margin
51.6%
Valuation Premium vs History
+0.5% premium
PE vs Historical
13.4 vs 13.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.5%
(market-implied from PE analysis)
1-Year Target
$17.12
(+1%)
2-Year Target
$17.20
(+1%)
3-Year Target
$17.29
(+2%)
3-Yr Target (if PE normalizes)
(PE: 13â13)
PE COMPRESSION
$17.08
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 507.1%)
$87.61
(+415%)
Base:
(SPY PE: 13.4, Growth: 507.1%)
$57.48
(+238%)
Bear:
(PE: 11.4, Growth: 507.1%)
$48.85
(+187%)
Share TBPH Analysis
Share this live TBPH analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (TBPH)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Jun 29, 2026
Daily AI digest
AI Retail Discussion Summary:
Zymeworks is set to acquire Theravance Biopharma for $929M. Theravance Biopharma shareholders will receive a contingent value right (CVR) for potential future royalties from ampreloxetine.
Key Retail Themes:
M&A activity in the biopharmaceutical sector
Potential future royalties from ampreloxetine
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:03 PM ET
Data refreshes hourly during market hours. Next update: 3:03 PM
Data refreshes hourly during market hours. Next update: 3:03 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TBPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
28 analysts |
$91 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 50 HOLD |
|
RAPP
Rapport Therapeutics, InâĻ |
STRONG BUY
16 analysts |
$64 | 48 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 42 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive TBPH Research Pages
